NYSE:ZYME - Zymeworks Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$16.05 +0.55 (+3.55 %)
(As of 04/19/2019 08:39 AM ET)
Previous Close$15.50
Today's Range$15.1672 - $16.19
52-Week Range$10.72 - $29.00
Volume142,695 shs
Average Volume116,933 shs
Market Capitalization$514.00 million
P/E RatioN/A
Dividend YieldN/A
Beta1.48
Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidates include ZW25, a bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer; ZW49, a bispecific antibody-drug conjugate that is in preclinical stage for treating breast and gastric cancers, and solid tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Celgene Corporation and Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; and Janssen Biotech, Inc., as well as a collaboration agreement with BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies targeting cytokine-receptor pathways. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Receive ZYME News and Ratings via Email

Sign-up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Previous SymbolNASDAQ:ZYME
CUSIPN/A
Phone604-678-1388

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$53.02 million
Book Value$5.64 per share

Profitability

Net Income$-36,560,000.00

Miscellaneous

Employees180
Market Cap$514.00 million
Next Earnings Date5/7/2019 (Estimated)
OptionableOptionable

Zymeworks (NYSE:ZYME) Frequently Asked Questions

What is Zymeworks' stock symbol?

Zymeworks trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZYME."

How were Zymeworks' earnings last quarter?

Zymeworks Inc (NYSE:ZYME) posted its quarterly earnings results on Wednesday, March, 6th. The company reported $0.29 EPS for the quarter, topping the Zacks' consensus estimate of $0.10 by $0.19. The business earned $28.93 million during the quarter, compared to the consensus estimate of $65 million. Zymeworks had a negative return on equity of 23.17% and a negative net margin of 68.95%. View Zymeworks' Earnings History.

When is Zymeworks' next earnings date?

Zymeworks is scheduled to release their next quarterly earnings announcement on Tuesday, May 7th 2019. View Earnings Estimates for Zymeworks.

What price target have analysts set for ZYME?

6 brokers have issued 12 month price objectives for Zymeworks' shares. Their forecasts range from $15.00 to $37.00. On average, they expect Zymeworks' share price to reach $24.3333 in the next twelve months. This suggests a possible upside of 51.6% from the stock's current price. View Analyst Price Targets for Zymeworks.

What is the consensus analysts' recommendation for Zymeworks?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zymeworks in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zymeworks.

Has Zymeworks been receiving favorable news coverage?

Media headlines about ZYME stock have been trending positive on Friday, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Zymeworks earned a media sentiment score of 2.7 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 5.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the company's share price in the next few days.

Who are some of Zymeworks' key competitors?

What other stocks do shareholders of Zymeworks own?

Who are Zymeworks' key executives?

Zymeworks' management team includes the folowing people:
  • Dr. Ali Tehrani, Co-Founder, Pres, CEO & Director (Age 47)
  • Mr. Neil A. Klompas C.A., CPA, CPA, CA, Chief Financial Officer (Age 47)
  • Dr. Anthony J. Polverino, Chief Scientific Officer & Exec. VP of Early Devel. (Age 56)
  • Dr. Diana F. Hausman, Chief Medical Officer (Age 56)
  • Dr. Surjit Dixit, VP of Technology (Age 46)

When did Zymeworks IPO?

(ZYME) raised $65 million in an initial public offering (IPO) on Friday, April 28th 2017. The company issued 4,500,000 shares at $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity served as the underwriters for the IPO and Cormark Securities was co-manager.

How do I buy shares of Zymeworks?

Shares of ZYME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Zymeworks' stock price today?

One share of ZYME stock can currently be purchased for approximately $16.05.

How big of a company is Zymeworks?

Zymeworks has a market capitalization of $514.00 million and generates $53.02 million in revenue each year. The company earns $-36,560,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis. Zymeworks employs 180 workers across the globe.

What is Zymeworks' official website?

The official website for Zymeworks is http://www.zymeworks.com.

How can I contact Zymeworks?

Zymeworks' mailing address is 1385 West 8th Avenue Suite 540, Vancouver A1, V6H 3V9. The company can be reached via phone at 604-678-1388 or via email at [email protected]


MarketBeat Community Rating for Zymeworks (NYSE ZYME)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  151 (Vote Outperform)
Underperform Votes:  120 (Vote Underperform)
Total Votes:  271
MarketBeat's community ratings are surveys of what our community members think about Zymeworks and other stocks. Vote "Outperform" if you believe ZYME will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZYME will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel